These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14552825)

  • 21. [Isolation, structure elucidation and synthesis of a hexapeptide from the hemodialysate of uremic patients].
    Bovermann G; Rautenstrauch H; Seybold G; Jung G
    Hoppe Seylers Z Physiol Chem; 1982 Oct; 363(10):1187-202. PubMed ID: 7141402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of two uremic toxins by nuclear magnetic resonance and mass spectrometry.
    Monti JP; Gallice P; Braguer D; Durand C; Murisasco A; Crevat A
    Adv Exp Med Biol; 1987; 223():223-6. PubMed ID: 3447439
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of platelet function by uremic middle molecules.
    Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
    Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of blood toxicity in chronic uremia by an improved chromatographic method.
    Politi L; D'Angelo AR; Caramia M; Molinaro M; Nicoletti R; Cerulli N; Moriggi M; Scandurra R
    Clin Exp Dial Apheresis; 1981; 5(3):277-84. PubMed ID: 7333038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparative isolation of middle molecular weight fractions from the hemofiltrate of patients with chronic uremia.
    Brunner H; Mann H; Essers U; Schultheis R; Byrne T; Heintz R
    Artif Organs; 1978 Nov; 2(4):375-7. PubMed ID: 743009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of small peptide in uremic serum by high-performance liquid chromatography.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1982 Mar; 228():292-7. PubMed ID: 7076752
    [No Abstract]   [Full Text] [Related]  

  • 28. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of sub-peak b4.2, middle molecule.
    Cueille G; Man NK; Sausse A; Farges JP; Funck-Brentano JL
    Artif Organs; 1981; 4 Suppl():28-32. PubMed ID: 7295091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin.
    Mingrone G; De Smet R; Greco AV; Bertuzzi A; Gandolfi A; Ringoir S; Vanholder R
    Clin Chim Acta; 1997 Apr; 260(1):27-34. PubMed ID: 9101098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Membrane and chromatography separation techniques for the preparative isolation of uremic toxins.
    Brunner H; Mann H
    Life Support Syst; 1983; 1 Suppl 1():199-206. PubMed ID: 6336410
    [No Abstract]   [Full Text] [Related]  

  • 32. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
    Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
    Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isotachophoretic separation of middle molecule peptides in uremic body fluids.
    Zimmerman L; Baldesten A; Bergström J; Fürst P
    Clin Nephrol; 1980 Apr; 13(4):183-8. PubMed ID: 7379369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach.
    Mishima E; Fukuda S; Mukawa C; Yuri A; Kanemitsu Y; Matsumoto Y; Akiyama Y; Fukuda NN; Tsukamoto H; Asaji K; Shima H; Kikuchi K; Suzuki C; Suzuki T; Tomioka Y; Soga T; Ito S; Abe T
    Kidney Int; 2017 Sep; 92(3):634-645. PubMed ID: 28396122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation of an immunosuppressive fraction in ultrafiltrate from uremic sera.
    Navarro J; Grossetete MC; Defrasne A; Touraine JL; Traeger J
    Nephron; 1985; 40(4):396-400. PubMed ID: 4022207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What remains of the "middle molecule" hypothesis today?
    Brunner H; Mann H
    Contrib Nephrol; 1985; 44():14-39. PubMed ID: 3886282
    [No Abstract]   [Full Text] [Related]  

  • 37. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
    Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
    Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent progress in the analysis of uremic toxins by mass spectrometry.
    Niwa T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(25):2600-6. PubMed ID: 19083276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.